The NCCN Oncology Research Program (ORP) strives to improve the quality of life for patients and reduce cancer-related deaths by advancing cancer therapies through research. Since the program’s establishment in 1999, the NCCN ORP has brought millions of dollars in research grants to investigators at NCCN Member Institutions. Research grants are provided to NCCN through collaborations with pharmaceutical and biotechnology companies; these grants are in turn used to support scientifically meritorious cancer research efforts.
NCCN ORP studies typically explore new avenues of clinical investigation and seek answers to important cancer-related questions. All studies are approved and funded through a scientific peer-review process and are overseen by the ORP.
This feature highlights an NCCN study funded through the grant mechanism.
A Phase I Dose-Escalation Safety and Tolerability Study of Mirvetuximab Soravtansine (IMGN853) and Gemcitabine in Patients With FRα-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple-Negative Breast Cancer
Principal Investigator: Mihaela Cristea, MD
Sub-Investigators: Edward Wang; Mark T. Wakabayashi, MD, MPH; Ernest Soyoung Han, MD, PhD; Thanh H. Dellinger, MD; Stephen J. Lee, MD; and Christopher P. Chung, MD
Conditions: Recurrent folate receptor α (FRα)–positive triple-negative (estrogen receptor–negative, HER2/neu-negative, progesterone receptor–negative) breast cancer, breast carcinoma, fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma, uterine corpus carcinoma, and ovarian cancer
Institution: City of Hope National Medical Center
This phase I trial is studying the side effects and best dose of mirvetuximab soravtansine (IMGN853) and gemcitabine hydrochloride for treating patients with recurrent FRα-positive ovarian, primary peritoneal, fallopian tube, endometrial, or triple-negative breast cancer (TNBC). This trial also includes 3 expanded disease-specific cohorts based on the recommended phase II dose for each disease site (breast [cohort A]; endometrial [cohort B]; and ovarian/primary peritoneal/fallopian tube [cohort C]) to evaluate efficacy in each cohort and help ensure adequate assessment of biological correlatives on biopsy (archival and posttreatment) material for cohort C.
Determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of gemcitabine when given in combination with IMGN853 to patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or TNBC
Explore toxicity, response rate, and progression-free survival in 3 expanded cohorts of heavily pretreated patients with FRα-positive TNBC, endometrial cancer, or ovarian/primary peritoneal/fallopian tube cancer, all treated with the initial RP2D
Provide additional safety data from the expanded cohorts to help inform on the RP2D for each cohort
Evaluate the relationship between intratumoral levels of DM4, tumoral expression of FRα, and plasma concentration of DM4 at 48 and 72 hours after the first dose
Determine the pharmacokinetics of DM4 and gemcitabine when given in combination
Evaluate the role of archival FRα expression as a substitute for the 48- to 72-hour expression in determining intratumoral concentration of DM4